Aclaris Therapeutics, Inc. (ACRS) company profile
Close on Nov 17, 2026Market cap $497.53MP/E –Yield –
About Aclaris Therapeutics
Pharmaceutical Preparations, SIC 2834
The company is a clinical-stage biopharmaceutical business that discovers and develops drug candidates for immuno-inflammatory conditions. Its pipeline includes biological therapies such as bosakitug, a monoclonal antibody, and ATI-052, a bispecific antibody targeting inflammatory pathways. It also designs small molecule kinase inhibitors, including ATI-2138 and ATI-9494, using its proprietary drug discovery platform. The company develops these experimental therapies for individuals with autoimmune, dermatological, and respiratory disorders, including atopic dermatitis and asthma, and seeks partnerships with external pharmaceutical firms to advance and commercialize its treatments.
The business relies entirely on third-party contractors to manufacture its preclinical and clinical supplies, maintaining no internal production facilities. Its clinical trial activities and licensing partnerships span international markets, including the United States, Europe, Japan, and South Korea, with global development rights excluding Greater China. The provided document does not identify the location of the company's corporate headquarters.
Summary of the business section of Aclaris Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Aclaris Therapeutics, Inc.
- Founded
- 2012
- Headquarters
- Wayne, PA
- Address
- 701 Lee Road, Suite 103 19087
- Phone
- (484) 324-7933
- Website
- www.aclaristx.com
- Employees
- 73, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers LLP, Philadelphia, Pennsylvania
Stock & identifiers
- Ticker
- ACRS
- Exchange
- Nasdaq
- IPO date
- Oct 8, 2015
- Shares outstanding
- 147M, Jul 31, 2026
- Public float
- $149.20M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1557746
- CUSIP
- 00461U105
- ISIN
- US00461U1051
- FIGI
- BBG003LF0QR9
- Share class FIGI
- BBG003LF0QS8
- LEI
- 5493000B2LQ9QTW1DF52
- EIN
- 46-0571712
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Neal Walker | CEO, Director | 1,543,886 |
| Hugh M. Davis | President and COO, Director | 45,425 |
| Roland Wilhelm Kolbeck | Chief Scientific Officer | 36,375 |
| Jesse Wayne Hall | Chief Medical Officer | 27,045 |
| Kevin Balthaser | Chief Financial Officer | 188,130 |
| James Loerop | Chief Business Officer | 192,260 |
| Joseph Monahan | Chief Scientific Officer | 265,855 |
| Christopher P. Molineaux | Director | 69,536 |
| William D. Humphries | Director | 45,105 |
| Vincent Milano | Director | 28,896 |
| Maxine Gowen | Director | 33,334 |
| Anand Mehra | Director | 2,637,976 |
| Andrew N. Schiff | Director | 459,995 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $3.38M | $3.83M | $1.47M | $19 | – |
| FY2024 Dr.Manion | $779.31K | $382.73K | $1.35M | $16 | – |
| FY2024 Dr.Walker | $1.45M | $1.63M | $1.35M | $16 | – |
| FY2023 | $7.16M | -$1.54M | $2.33M | $7 | – |
| FY2022 | $5.84M | $6.65M | $3.12M | $108 | – |
| FY2021 | $6.85M | $12.15M | $4.05M | $770 | $126 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Neal Walker Chief Executive Officer | $615.00K | $828.43K | $1.58M | $350.55K | – | $3.38M | +134% |
| Kevin Balthaser Chief Financial Officer | $446.00K | $310.64K | $548.44K | $171.71K | $14.00K | $1.49M | +35% |
| James Loerop Chief Business Officer | $416.00K | $336.80K | $520.15K | $160.16K | $14.00K | $1.45M | – |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Oct 8, 2015
- Offer price
- $11.00
- Securities offered
- 5,000,000
- Gross proceeds
- $55.00M
- Exchange
- Nasdaq
- First trading day
- Oct 6, 2015
- First-day close
- $11.000.0%
- Lock-up ends (est.)
- Apr 3, 2016
“The initial public offering price is $11.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 73 total employees, of which 69 were full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Oct 11, 2019 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Dec 3, 2018 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Nov 9, 2017 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Aug 8, 2017 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Mar 30, 2016 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Oct 8, 2015 | IPO | Initial public offering priced (424B4 prospectus) |
| Oct 2, 2015 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?